Orbit Biomedical focuses on developing novel surgical devices and procedures designed to deliver curative therapies. Our team brings years of expertise in biomedical engineering, medical device development, clinician training, ophthalmology and curative therapies. The current focus of our efforts is on delivery to the subretinal space for the treatment of blinding eye diseases.
Degeneration of the retina is associated with many blinding conditions.
Many severe blinding diseases are due to degeneration of the tissues of the retina, the thin layer of tissue which lines the inside of the back of the eye. The retina detects light coming in through the lens, and translates the light signals into neural signals to be sent to the brain. Click here to learn more about the retina and how the eye works.
Inherited blinding diseases (including retinitis pigmentosa, Leber’s congenital amaurosis, achromatopsia, and choroideremia) are often caused by mutations in genes which affect cells in the retina. Other more common diseases, such as age-related macular degeneration (AMD), are also associated with loss of functional retinal tissue.
The subretinal space is a preferred location for curative therapies
The subretinal space is the space between the retinal pigment epithelium (RPE) and choroid layer. The eye is an excellent target organ for curative therapies due to its accessibility, small size, compartmentalization and relative immune privileged status. Placing curative therapeutics directly in the subretinal space allows direct access to critical target tissues.
Currently, delivery requires vitrectomy and injection through the retinal tissue
The subretinal space has traditionally been accessed via an injection across the eye in conjunction with vitrectomy (removal of the vitreous, the gel-like substance that fills the eye). This procedure may result in unwanted side-effects such as retinal tears1 and the development of cataracts2. Product leakage out of the subretinal space and into the vitreous is also a problem, where it may cause inflammation in the eye3.
Orbit Biomedical: Access to the subretinal space without vitrectomy and without the need to pierce the retina
Orbit Biomedical is developing a novel device and procedure to enable the subretinal space to be accessed without removal of the vitreous, and without the need to make multiple holes in the retina. Our key focus is on the safety, accuracy and consistency of delivery.
Collaboration with expert surgeon faculty
In addition to focusing on safety, accuracy and consistency, our biomedical engineers work with expert surgeon faculty to streamline the user interface and make our platform as simple and easy to use as possible. Orbit Biomedical’s team has expertise in human factors engineering, surgical procedure development, surgical instrumentation development, surgical visualization tools, microfluidics and catheter technologies.
 Ramkissoon, Yashin D et al. “Risk of iatrogenic peripheral retinal breaks in 20-G pars plana vitrectomy.” Ophthalmology 117 9 (2010): 1825-30.
 Feng, H and Ron Afshari Adelman. “Cataract formation following vitreoretinal procedures.” Clinical ophthalmology (2014).
 Hsu, S. Tammy et al. “Volumetric Measurement of Subretinal Blebs Using Microscope-Integrated Optical Coherence Tomography.” Translational vision science & technology (2018).